Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells
- 30 November 2012
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica-The Hematology Journal
- Vol. 97 (12), 1904-1908
- https://doi.org/10.3324/haematol.2012.066399
Abstract
Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 has been shown to improve leukemia-free survival in acute myeloid leukemia in a phase III trial. For this study, treatment efficacy was determined among 145 trial patients with morphological forms of acute myeloid leukemia as defined by the French-American-British classification. Leukemia-free survival was strongly improved in M4/M5 (myelomonocytic/monocytic) leukemia but not in M2 (myeloblastic) leukemia. We also analyzed histamine H-2 receptor expression by leukemic cells recovered from 26 newly diagnosed patients. H-2 receptors were typically absent from M2 cells but frequently expressed by M4/M5 cells. M4/M5 cells, but not M2 cells, produced reactive oxygen species that triggered apoptosis in adjacent natural killer cells. These events were significantly inhibited by histamine dihydrochloride. Our data demonstrate the presence of functional histamine H2 receptors on human AML cells and suggest that expression of these receptors by leukemic cells may impact on the effectiveness of histamine-based immunotherapy.Keywords
This publication has 20 references indexed in Scilit:
- Analyzing Cell Death Events in Cultured LeukocytesPublished by Springer Science and Business Media LLC ,2011
- Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemiaBlood, 2011
- Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemiaTrials, 2011
- Addressing the Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 in Treating Acute Myeloid Leukemia: A Bayesian Meta-AnalysisCancer Investigation, 2011
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemiaExpert Review of Hematology, 2010
- Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 StudyJournal of Clinical Oncology, 2010
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2008
- Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype inductionBlood, 2006